文献速递炎症性肠病

炎症性肠病缓解期患者停用抗肿瘤坏死因子治疗:GETECCU 随机安慰剂对照临床试验

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
PubMed 文献 · Gut · 2025-02-06

前瞻性四盲多中心随机对照试验纳入临床缓解超过6个月的溃疡性结肠炎或克罗恩病患者140例,随机维持或停用抗TNF治疗,均继续免疫调节剂。12个月持续临床缓解率维持组59/70(84%)与停用组53/70(76%)相似;停用组客观活动指标更高。

要点

  • 筛选的临床、内镜及影像学缓解的IBD患者停用抗TNF后1年持续临床缓解率与维持组相似。
  • 停用组随访末粪钙卫蛋白>250 µg/g的比例更高(p=0.01)。
  • 两组不良事件发生率均为69%,严重不良事件维持组4% vs 停用组7%。

核心结论

  • 在筛选的临床、内镜及影像学缓解的IBD患者中,停用抗TNF对1年持续临床缓解无影响,但停用者客观活动标志物更高。

研究设计与样本

  • 前瞻性、四盲、多中心、随机对照试验。
  • 纳入临床缓解>6个月且无严重内镜(克罗恩病还包括影像学)病变的溃疡性结肠炎或克罗恩病患者。
  • 随机分为维持抗TNF治疗组(MA)或停用抗TNF组(WA),所有患者均维持免疫调节剂。
  • 随访至第12个月或临床复发。
  • 共随机140例,MA组70例,WA组70例。

主要发现

  • 12个月持续临床缓解比例MA组59/70(84%),95%CI=74%至92%;WA组53/70(76%),95%CI=64%至85%。
  • 随访末显著内镜病变比例MA组8.5% vs WA组19%(p=0.1)。
  • 随访末粪钙卫蛋白>250 µg/g的患者比例WA组更高(p=0.01)。
  • 至少发生一次不良事件的患者比例两组均为69%。
  • 严重不良事件比例MA组4% vs WA组7%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment versus those who maintain it. SECONDARY OBJECTIVES: to evaluate the effect of anti-TNF withdrawal on relapse-free time, endoscopic and radiological activity, safety, quality of life and work productivity; and to identify predictive factors for relapse. DESIGN: Prospective, quadruple-blind, multicentre, randomised, controlled trial. Patients with ulcerative colitis or Crohn's disease in clinical remission for >6 months and absence of severe endoscopic (and radiological in Crohn's disease) lesions were randomised to maintain anti-TNF treatment (maintenance arm (MA)) or to withdraw it (withdrawal arm (WA)). All patients maintained immunomodulators. Patients were followed-up until month 12 or up to clinical relapse. RESULTS: One-hundred forty patients were randomised: 70 were allocated to the MA and 70 to the WA. The proportion of patients with sustained clinical remission at 12 months was similar in the MA and WA: 59/70 (84%), 95% CI=74% to 92% versus 53/70 (76%), 95% CI=64% to 85%. The proportion of patients with significant endoscopic lesions at the end of follow-up was 8.5% in the MA and 19% in the WA (p=0.1); a higher proportion of patients had faecal calprotectin >250 µg/g at the end of follow-up in the WA (p=0.01). The same percentage of patients in both groups had at least one adverse event (69%). The proportion of patients with serious adverse events was also similar in both groups (4% in MA vs 7% in WA). CONCLUSION: Anti-TNF withdrawal in selected patients with IBD in clinical, endoscopic and radiological remission has no impact on sustained clinical remission at 1 year although objective markers of activity were higher in patients who withdrew treatment. TRIAL REGISTRATION NUMBER: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001410-10 https://clinicaltrials.gov/study/NCT02994836.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Gisbert JP, Donday MG, Riestra S, et al. Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU. Gut. 2025. PMID: 39794921. doi:10.1136/gutjnl-2024-333385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。